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Background. The efficacy of N-acetylcysteine (NAC) for pre-
venting contrast nephropathy is uncertain. We performed a sys-
tematic review and meta-analysis to assess the efficacy of NAC
for preventing contrast nephropathy after administration of in-
travenous contrast media.
Methods. Data were obtained from searching MEDLINE
(1969–2003) and EMBASE (1988–2003), Cochrane Controlled
Clinical Trial Registry (2002, Volume 3), and conference pro-
ceedings. We considered all randomized studies that compared
changes in renal function between groups that received and did
not receive NAC. Studies in which the control group also re-
ceived active therapy were excluded, although cointervention
directed at both groups was permitted. Two reviewers indepen-
dently extracted quantitative and qualitative data. Disagree-
ments were resolved by consensus with the aid of a third party.
Results. Fifteen studies with a total of 1776 patients satisfied
inclusion and exclusion criteria. Contrast nephropathy was typ-
ically defined by an increase in serum creatinine of 0.5 mg/dL
within 24 to 48 hours of contrast administration. The pooled
random effect relative risk was 0.65 (0.43–1.00, P = 0.049), indi-
cating that NAC significantly reduced the incidence of contrast
nephropathy. However, the effect of NAC was not statistically
significant in several prespecified subgroup analyses, and the
results were not robust to the addition of hypothetical new or
unidentified randomized trials. There was evidence of signif-
icant heterogeneity in NAC effect across studies (Q = 26.3,
P = 0.02). Random effects meta-regression did not implicate
identified differences in participant or study characteristics as
responsible for the observed heterogeneity.
Conclusion. NAC may reduce the incidence of acutely in-
creased serum creatinine after administration of intravenous
contrast, but this finding was of borderline statistical signifi-
cance, and there was significant heterogeneity between trials.
Before NAC becomes the standard of care for all patients re-
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ceiving intravenous contrast, new randomized trials evaluating
its effect on clinically relevant outcomes are required.
Contrast nephropathy is a common cause of acute renal
failure among hospitalized patients, and is a recognized
complication of diagnostic and therapeutic procedures
in which intravenous contrast agent is required [1]. Al-
though its incidence varies widely depending on the pop-
ulation studied, acutely elevated serum creatinine after
the administration of intravenous contrast is associated
with increased morbidity and mortality [2].
Use of nonionic low osmolarity contrast media and
preprocedural hydration with intravenous fluids both
appear to decrease the risk of contrast nephropa-
thy [3–5]. Recent work suggests that administration of
N-acetylcysteine (NAC) further reduces the likelihood of
contrast nephropathy [6, 7], but other trials have failed
to confirm this finding [8, 9].
We performed a systematic review and meta-analysis of
published and unpublished randomized trials to quantify
the effect of NAC on contrast nephropathy. Our goal was
to synthesize the available information on this topic, with
extensive use of sensitivity analysis to test the robustness
of our conclusions.
METHODS
Search strategy
Two reviewers searched MEDLINE (1969 to May
2003) and EMBASE (1988 to May 2003) in duplicate
using the free text/textword terms [(acetylcysteine or
n-acetylcysteine) and (renal OR kidney OR contrast)].
Two reviewers examined reference lists from review arti-
cles identified in the search, and searched abstracts from
the American Society of Nephrology (1999–2002), Amer-
ican Heart Association (2000–2003), American College
of Cardiology (1999–2003), and Society of Interven-
tional Radiology (2002–2003) meetings. Two reviewers
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examined the reference lists of investigations meeting our
inclusion criteria for other potentially relevant studies.
Finally, one reviewer searched the Cochrane Controlled
Clinical Trials Registry, the Science Citation Index, and
the Database of Abstracts and Reviews using only the
term (acetylcysteine or n-acetylcysteine). Any trial that
was deemed worthy of manual review was recorded, as
well as the reasons for subsequent exclusion (if appli-
cable). We did not restrict the search to the English
language.
Study selection
The search strategy and data abstraction were defined
by a prospective protocol. To minimize the effects of pub-
lication bias, all randomized studies that compared the in-
cidence of changes in renal function between groups that
received and did not receive NAC were eligible for in-
clusion, whether published or unpublished. We excluded
data comparing NAC to another active therapy. How-
ever, trials that specified cointervention (i.e., intravenous
saline) were included, providing that it was given to both
groups.
Validity assessment and data extraction
We assessed qualitative details of study methodology
that were likely to influence internal validity [10, 11].
We did not attempt to assess allocation concealment in
blinded studies, although certain NAC preparations may
be more amenable to concealment than others because
of differences in taste. If multiple publications from the
same group were found, the studies were carefully re-
viewed to ensure that no data was analyzed in dupli-
cate. All data was extracted separately by two authors
and results compared; disagreements were resolved by
consensus with the aid of a third party. Extracted data
was recorded on a standardized form. At least two at-
tempts were made to contact the corresponding and/or
first author on every included study. Additional data was
provided and the original data was confirmed by 14 of the
15 original authors.
Outcome measures
The primary outcome was the pooled estimate of the
relative risk (RR) for contrast nephropathy in patients
randomized to receive NAC, compared with those who
did not (CN). The definition of “contrast nephropathy”
was similar in the included studies (Table 1). Although
pooling results from trials that used slightly different
definitions may affect the estimated incidence of con-
trast nephropathy, it would not affect the difference in
outcomes between treatments. Secondary outcomes in-
cluded the relative risk of requiring acute dialysis treat-
ment and the differential change in serum creatinine be-
tween groups.
Quantitative data synthesis
We first performed a funnel plot for the primary out-
come, considering only studies that have successfully
undergone peer review (published or in press as full
manuscripts) [12]. We formally tested for the presence
of publication bias using Begg’s test [13]. Next, data from
the 15 eligible studies were combined using random ef-
fect models calculated by the method of Der Simonian
and Laird [14]. Heterogeneity was calculated using the in-
verse variance method, and the Q statistic was employed
to provide a numerical measure of heterogeneity for each
analysis [15]. This statistic tests the null hypothesis that
the underlying effect measured by each of the pooled
studies is equivalent. When P < 0.1 for Q, this assump-
tion is invalid and heterogeneity exists. All measures of
effect refer to the risk of outcomes in patients who re-
ceived NAC, compared with those who did not. Differ-
ences in categorical outcomes were expressed as relative
risks; differences in continuous outcomes were expressed
as weighted mean differences.
We used random effects meta-regression [16] to ex-
amine whether certain study characteristics modified the
effect of NAC on the incidence of contrast nephropathy.
In each meta-regression analysis, the incidence of con-
trast nephropathy was the dependent variable, and NAC
use plus one study characteristic (based on participants in
both groups: overall proportion of diabetic participants,
mean baseline serum creatinine, mean volume of con-
trast administered) were independent variables. Finally,
we estimated the effect size and number of participants
in hypothetical (new or unidentified) trials that would
significantly change our results.
All analyses were performed using Intercooled Stata
8.0 (Stata Corporation, College Station, TX, USA). The
level of statistical significance was set at P < 0.05.
RESULTS
Trial flow and study characteristics
The abstracts of 2476 studies were reviewed. Of these,
71 were deemed worthy of further exploration and were
retrieved for review. Sixteen potentially eligible random-
ized studies were found. Of these, one was excluded be-
cause the control group received theophylline [abstract;
Bader et al, J Am Soc Nephrol 13:447A, 2002). Fifteen
studies satisfied inclusion and exclusion criteria and ap-
pear in Table 1. Several studies that were initially pub-
lished as abstracts were subsequently published as full
papers. To avoid including data in duplicate, we there-
fore excluded the abstracts, and included only the full
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papers. The remaining studies did not examine the effect
of NAC on contrast nephropathy.
Of the 15 studies for which the relative risk of the
primary outcome could be calculated, nine had already
been published [6–9, 17–21], three were in press [22–24],
and three were published only in abstract form [abstract;
Loutrianakis et al, J Am Coll Cardiol, 41:327A, 2003; Le
Feuvre et al, J Am Coll Cardiol 41:192A, 2003; Kahlon
et al, Circulation 106:11–691, 2002). Information on the
individual studies appears in Tables 1–4. All studies were
randomized, although allocation sequence was not al-
ways specified, and only six studies were double blind.
A power calculation and the characteristics of ineligible
patients were not provided in most studies.
Quantitative data synthesis
Meta-analysis (contrast nephropathy). The plot of ef-
fect size against its precision showed a relative absence
of small published studies that found the relative risk
of contrast nephropathy with NAC to be >1, suggesting
at least some degree of publication bias (Fig. 1). Begg’s
test confirmed the visual impression of publication bias
(P = 0.02). Inspection of the data using a Galbraith plot
showed no obvious correlation between effect of NAC
and year of publication, country of origin, protocol for
administration of intravenous fluid, or definition of con-
trast nephropathy (data not shown).
We first analyzed all 15 trials to evaluate the primary
end point. The Q statistic suggested significant hetero-
geneity across studies (Q = 26.3, P = 0.02). The random
effect relative risk was of borderline statistical signifi-
cance: 0.65 (0.43–1.0, P = 0.049), suggesting that NAC
significantly reduced the incidence of contrast nephropa-
thy (Fig. 2).
Restricting the analysis to those studies which had
successfully completed peer review (N = 12) did not
change our results—RR (CN): 0.55 (0.35–0.85, P < 0.01),
and substantial heterogeneity remained. The relative
risk of contrast nephropathy associated with NAC treat-
ment was statistically nonsignificant when analysis was
limited to trials which studied only coronary angiogra-
phy/angioplasty (N = 11)—RR (CN): 0.62 (0.41–1.01,
P = 0.06). Finally, limiting analyses to trials which used a
more stringent definition of CN (a single criterion rather
than a composite of two or more criteria, N = 7) also ren-
dered the effect of NAC statistically nonsignificant—RR
(CN): 0.64 (0.30–1.35, P = 0.24).
Sensitivity analysis—Risk of contrast nephropathy
We estimated how large a sample size would be re-
quired for a hypothetical new or undetected trial to
change our conclusions (i.e., render the pooled RR of
contrast nephropathy associated with NAC therapy sta-
tistically nonsignificant). We assumed that such a study
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Table 2. Study quality
Number Reasons for Inclusion and Cointervention Characteristics of
Allocation lost to Loss to loss to exclusion potentially rejected or
sequence follow-up follow-up follow-up Power criteria unequal between ineligible patients
First author adequatea reported <10% of N providedb calculation specified groupsc listed
Oldemeyer [24] yes yes yes yes yes yes/yes no no
Loutrianakis yes no – – no yes/yes yes no
Baker [21] yes yes yes yes yes yes/yes yes no
Le Feuvre yes yes yes – no yes/no no no
Kay [7] yes yes yes yes yes yes/yes no yes
Durham [8] yes yes yes yes no yes/yes yes no
Briguori [17] yes yes yes – no yes/no no no
Diaz-Sandoval [18] yes yes yes – no yes/yes yes no
Shyu [19] NS yes yes – yes yes/yes no no
Vallero [20] NS yes yes – no yes/yes no no
Allaqaband [9] yes yes yes – no yes/no no no
Kahlon NS yes yes – no yes/yes yes no
Ochoa [23] NS yes no no no yes/no yes no
Azmus [22] NS no – – yes yes/yes yes no
Tepel [6] yes yes yes – no yes/yes no no
NS, not specified. All studies were randomized controlled trials comparing NAC to a control group with no specific intervention. In all studies, both groups received
intravenous fluids according to protocols that were identical for NAC and control groups.
aWe did not assess the success of allocation concealment.
bThis characteristic was not tabulated for studies with no loss to follow-up.
cFor example, trials in which one group was deliberately given less intravenous saline, or trials in which the volume of intravenous saline used could be varied at the
discretion of clinicians/the investigators. In general, variable cointervention is a greater potential source of bias in trials without adequate blinding and concealment.
would show that NAC substantially increased the risk of
contrast nephropathy (RR of 1.25) and find the incidence
of CN to be 12% in the control group [7]. Using a random
effects model, the required N was 50, indicating that the
pooled result was not robust to the addition of new trials.
Requirement for dialysis
Complete data on the need for dialysis were available
from 12 trials. However, in seven of these, no participants
in either group required dialysis, making it impossible
to calculate a relative risk. The pooled relative risk of
dialysis associated with NAC in the remaining five trials
was 0.90 (95% CI: 0.24–3.37, P = 0.77).
Sensitivity analyses—Requirement for dialysis
We found that a new trial would need to be very large
(or to enroll participants with a high likelihood of requir-
ing dialysis) to render the pooled risk of dialysis statisti-
cally lower in NAC recipients. For example, a single trial
that found that NAC reduced the absolute risk of dialysis
by 1.6% [19] would require 1200 subjects to establish a
significantly lower pooled risk of dialysis among NAC re-
cipients. Alternatively, assuming that NAC reduced the
risk of dialysis by 50%, a new trial with 200 participants
would require that 26% of control participants received
dialysis to render the pooled risk reduction for dialysis
among NAC recipients statistically significant.
Evaluation of heterogeneity
There was evidence of significant heterogeneity
between studies in the relative risk of contrast nephropa-
thy with NAC therapy. Although all studies adminis-
tered intravenous saline to both groups, the exact volume/
duration of infusion was not specified (or could be modi-
fied at the discretion of the investigator) in six studies [8,
18, 22, 23] [abstract; Loutrianakis et al, J Am Coll Car-
diol 41:327A, 2003; Kahlon et al, Circulation 106:11–691,
2002 (of which two were unblinded) [8], raising the possi-
bility that saline was differentially administered between
groups, either randomly or deliberately. In one trial, the
NAC group was purposely given less intravenous saline
[21]. Although NAC did not significantly prevent CN in
six of these seven trials, the effect of NAC remained non-
significant when results from the remaining eight trials
were combined (RR 0.58, CI 0.31–1.09, P = 0.09), and
significant heterogeneity remained (P = 0.08).
To evaluate the possibility that identifiable differences
between trials accounted for the heterogeneity, we per-
formed random effects meta-regression examining one
covariate at a time. These analyses demonstrated no sig-
nificant relationships between the effect of NAC on con-
trast nephropathy and the proportion of participants with
diabetes mellitus (P = 0.68), the average volume of con-
trast agent required (P = 0.85), average baseline serum
creatinine (P = 0.53), or total number of study partici-
pants (P = 0.96), suggesting that these variables were not
responsible for the heterogeneity. However, the effect of
NAC was less likely to be protective in trials that had not
completed peer review (P = 0.03).
Fourteen of 15 trials used non-ionic, low-molecular-
weight intravenous contrast, and in 12 trials NAC was
given over a 48-hour period. In three studies, partici-
pants received NAC only on the day that intravenous
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Table 3. Results for categorical outcomes
Need for
% CN in Need for dialysis in
% CN in NAC RR of CN dialysis in NAC
First author Control N NAC N controls recipients (95% CI) controls recipients
Oldemeyer [24] 47 49 6.4% 8.2% 1.28 (0.30–5.41) 0% 0%
Loutrianakis 23 24 13.0% 25.0% 3.83 (0.46–31.8) 4.3% 4.2%
Baker [21] 39 41 20.5% 4.9% 0.24 (0.05–1.05) 0% 0%
LeFeuvre 60 60 3.4% 5% 1.5 (0.26–8.66) 0% 0%
Kay [7] 98 102 12.2% 3.9% 0.32 (0.11–0.96) 0% 0%
Durham [8] 41 38 22.0% 26.3% 1.20 (0.55–2.63) NS NS
Briguori [17] 91 92 11.0% 6.5% 0.59 (0.23–1.57) 1.1% 0%
Diaz-Sandoval [18] 29 25 44.8% 8.0% 0.18 (0.04–0.72) 0% 0%
Shyu [19] 61 60 24.6% 3.3% 0.14 (0.03–0.57) 1.6% 0%
Vallero [20] 53 47 7.5% 8.5% 1.13 (0.30–4.26) 0% 0%
Allaqaband [9] 40 45 15.3% 17.7% 1.19 (0.45–3.12) 0% 4.4%
Kahlon 24 27 17.1% 29% 1.71(0.50–5.89) 0% 0%
Ochoa [23] 44 36 25.0% 11.1% 0.44 (0.15–1.28) 0% 0%
Azmus [22] 201 196 8.4% 7.1% 0.84 (0.43–1.67) 0.5% 0.5%
Tepel [6] 42 41 21.4% 2.4% 0.11 (0.02–0.86) 0% 0%
Abbreviations are: NAC, n-acetylcysteine; CN, contrast nephropathy; RRR, relative risk reduction; NS, not specified; 95% CI, 95% confidence interval.
Table 4. Results for continuous outcomes
Change in Change in
Control NAC SCr in SCr in NAC
First author N N controls recipients
Oldemeyer [24] 47 49 −0.05 −0.01
Loutrianakis 23 24 −0.055 ± 0.26 0.15 ± 0.64
Baker [21] 39 41 0.05 ± 0.31 −0.08 ± 0.34
Le Feuvre 60 60 0.07 ± 0.43 −0.02 ± 0.29
Kay [7] 98 102 0.02 −0.13
Durham [8] 41 39 NS NS
Briguori [17] 91 92 −0.01 ± 0.41 −0.04 ± 0.40
Diaz-Sandoval [18] 29 25 0.3 ± 0.06 −0.1 ± 0.06
Shyu [19] 61 60 0.24 ± 0.56 −0.29 ± 0.41
Vallero [20] 53 47 0.04 ± 0.16 0.04 ± 0.19
Allaqaband [9] 40 45 0.09 ± 0.3 0.01 ± 0.6
Kahlon 24 27 NS NS
Ochoa [23] 44 36 0.23 ± 0.64 0.06 ± 0.72
Azmus [22] 201 196 0.10 ± 0.28 0.08 ± 0.21
Tepel [6] 42 41 0.2 ± 0.6 −0.4 ± 0.4
Abbreviations are: NAC, n-acetylcysteine; CN, contrast nephropathy; SCr,
serum creatinine (mg/dL); NS, not specified.
contrast was administered. However, exclusion of these
three trials did not significantly reduce the heterogene-
ity of NAC effect or change results. When only the six
double-blinded trials were combined, heterogeneity was
reduced (P for heterogeneity >0.1), and the overall effect
of NAC on contrast nephropathy was rendered statisti-
cally nonsignificant (RR 0.61, 95% CI: 0.33–1.13).
Other clinical effects
We performed a pooled analysis of the differential
change in serum creatinine between groups for trials
that reported the standard deviation of this change. The
weighted mean increase in serum creatinine was signif-
icantly lower in NAC recipients compared with control
(0.20 mg/dL lower, 95% CI 0.05–0.35, P = 0.01). Two tri-
–4
–2
0
2
In
(R
R)
0 .5 1
SE of In(RR)
Fig. 1. Funnel plot of effect size versus precision of effect size. The
figure plots an index of effect size (ln relative risk) against its preci-
sion [standard error (SE) of ln relative risk]. There is an absence of
small trials that found an increased incidence of contrast nephropathy
associated with N-acetylcysteine (NAC).
als provided information on mean length of stay by group,
which was significantly lower among NAC recipients in
one (3.4 vs. 3.9, P = 0.02) [7], but not the other (5.4 vs. 5.4,
P = 0.80) [23]. No trial reported a significantly increased
risk of adverse events among NAC recipients.
DISCUSSION
This systematic review combined results from 15 ran-
domized studies evaluating the effect of NAC on the in-
cidence of acutely elevated serum creatinine in people
receiving intravenous contrast. In our primary analysis,
the use of NAC was associated with a reduction in the
incidence of contrast nephropathy, but this difference
was of borderline statistical significance (P = 0.049), and
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0.24 (0.05,1.05)
1.20 (0.55,2.63)
0.59 (0.23,1.57)
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0.11 (0.02,0.86)
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Fig. 2. Relative risk of contrast nephropa-
thy associated with NAC: All identified tri-
als. Relative risk refers to the risk of contrast
nephropathy in the N-acetylcysteine (NAC)
group, compared with control. The squares
represent the point estimate of relative risk
for each study, and their size is proportional
to their weight in the pooled estimate of rela-
tive risk (represented by the diamond). Bars
indicate 95% CI. Q = 26.3, P = 0.02.
the pooled mean difference in serum creatinine between
groups was small (0.2 mg/dL).
Sensitivity analyses showed that the pooled estimate of
NAC effect was not robust to the inclusion of hypotheti-
cal new or unidentified studies, and the protective effect
of NAC was observed in one prespecified subgroup of
trials (randomized trials which have completed peer re-
view), but not others (trials considering cardiac interven-
tions only, or those in which a more stringent definition
of CN was used). The effect of NAC was also statistically
nonsignificant in post-hoc analyses, which excluded trials
with potentially unequal intensity of cointervention, and
those that were not double-blinded, suggesting that dif-
ferences in study design may have influenced the effect of
NAC. Finally, there was no reduction in the risk of dial-
ysis between treatment groups. Together, these findings
may cast doubt on whether NAC truly improves clinical
outcomes in people receiving intravenous contrast.
Although there was evidence of significant heterogene-
ity in the effect of NAC, meta-regression did not impli-
cate measured differences in participant characteristics
or study interventions as responsible for this. In particu-
lar, mean contrast dose, mean baseline serum creatinine,
and the proportion of diabetic patients enrolled did not
appear to influence the efficacy of NAC. While the lim-
itations of meta-regression are well known [16, 25], this
technique may be more susceptible to type I than type II
error, suggesting that the covariates we considered do not
explain the observed heterogeneity. However, because
the effect of NAC appeared more homogeneous when
only double-blinded studies, or those that ensured equal
cointervention were included, it is possible that differ-
ences in study quality were responsible for some of the
heterogeneity. Finally, although we were unable to show
a relation between the effect of NAC and the dose or tim-
ing of its administration, it is possible that the different
NAC protocols used resulted in heterogeneity.
The pathophysiology of contrast nephropathy is well
described, and is caused by a combination of toxic and
ischemic effects on renal tubular and medullary cells [26].
However, the basis for the nephroprotective action of
NAC is unknown. It has been suggested that this effect is
mediated by scavenging oxygen free radicals [27, 28], or
by enhancing the vasodilatory effects of nitric oxide [29].
Alternatively, NAC may exert a direct protective effect
on renal cells that have sustained ischemic injury [30, 31].
The mechanism by which NAC acts is potentially rel-
evant, because acute elevations in serum creatinine after
administration of contrast media are not always caused by
contrast nephropathy. For example, acute tubular necro-
sis or prerenal azotemia might occur in patients with
acute coronary syndromes, and atheroemboli might be
triggered by coronary angiography. Although in theory
such episodes would be evenly balanced between treat-
ment arms in randomized trials, this is not always the
case, especially in smaller studies. Even for large studies,
acute increases in serum creatinine that are not caused
by contrast nephropathy would be expected to bias the
estimate of NAC effect toward the null. Thus, unmea-
sured differences in the acuity of illness of participants, or
the incidence of atheroemboli between studies may have
been responsible for some of the observed heterogene-
ity. Because atheroemboli does not occur after contrast-
enhanced computed tomography, a protective effect of
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NAC might be most apparent in this population. We spec-
ulate that this is why NAC appeared most beneficial in the
only trial which studied patients undergoing computed
tomography [6]. However, even in this trial, there was no
reduction in the incidence of clinically relevant outcomes
such as the need for dialysis.
We found evidence of publication bias, reflected by an
absence of smaller published trials, which show no pro-
tective effect of NAC. Our primary analysis considered all
identified trials, whether or not they had completed peer
review. In a secondary analysis, we included only those
trials which were published or in press, and found that
NAC appeared to be more effective in this group. Be-
sides publication bias, an alternate explanation for this
finding might be that the unpublished trials are of poorer
quality than the others. In our opinion, review of Table 2
suggests that this is unlikely. Our decision to include all
identified studies probably reduced the effect of publica-
tion bias. However, if such bias remains, the true effect of
NAC is likely smaller than our primary analysis suggests.
Data from observational studies suggest that serum
creatinine will return to baseline in most individuals
with contrast nephropathy [2, 32]. Therefore, prevention
of contrast nephropathy would be expected to improve
health outcomes by reducing the frequency with which
acute dialysis is required, or by further increasing the
likelihood of complete recovery. Unfortunately, data on
the ability of NAC to achieve these clinical objectives are
sparse. No study reported long-term outcomes of partic-
ipants with contrast nephropathy, and acute dialysis oc-
curred too infrequently to determine whether it was less
common among NAC recipients. To conclusively demon-
strate clinically relevant benefit, future trials would need
to enroll participants at higher risk for adverse renal out-
comes, collect data on longer-term outcomes, or both.
If NAC therapy simply reduces the risk of transient
increases in serum creatinine without improving other
clinical outcomes, it might still decrease healthcare costs
by reducing the duration of hospitalization in patients
receiving intravenous contrast. Unfortunately, only one
study compared this outcome between groups. Although
these authors found a significant reduction in length of
stay in the NAC arm, the absolute difference was small
(0.5 days), and it is unclear how this would translate to
centers which perform most procedures requiring intra-
venous contrast on outpatients [7]. Thus, in our opinion,
the evidence that routine use of NAC would reduce length
of hospital stay in patients receiving intravenous contrast
is inconclusive.
A recent editorial suggested that NAC should be given
to all patients at risk for contrast nephropathy [33]. Given
the lack of evidence that NAC prevents clinically rele-
vant outcomes, we believe that this recommendation is
premature, and that further studies are required before
periprocedural administration of NAC becomes the stan-
dard of care. In addition, the costs associated with the
prescription and administration of NAC are unknown.
Therefore, a formal economic evaluation might assist
in determining whether NAC should be routinely pre-
scribed before administration of intravenous contrast—
and if so, to which patients. Finally, even if NAC truly re-
duces the incidence of contrast nephropathy, physicians
must remember the importance of other strategies, such
as avoiding unnecessary contrast studies and ensuring ad-
equate intravenous hydration.
Strengths of our study include the comprehensive
search strategy and the careful statistical methodology
used. We identified 15 trials with a total of 1776 sub-
jects, considerably more than a recently published meta-
analysis, which included only 805 participants [34]. These
authors found that NAC reduced the risk of contrast
nephropathy in their primary analysis and several sen-
sitivity analyses. Unfortunately, they were unable to
include several recently completed studies in which the
effect of NAC was nonsignificant, including the largest
trial to date [22]. Unlike the findings of Birck et al, our
results indicate some uncertainty as to whether NAC ac-
tually reduces the risk of contrast nephropathy. This dis-
crepancy appears to be due to our inclusion of the more
recent data. However, both meta-analyses are limited by
differences in the definitions of contrast nephropathy and
NAC protocols in the various studies, and probably other
poorly quantified factors. Because of the multiple anal-
yses performed, conclusions drawn from any particular
subset of studies (those considering only cardiac interven-
tions, for example) should be interpreted with caution.
Nonetheless, our systematic review summarizes what is
known about the effect of NAC on contrast nephropathy,
and suggests that further work is needed to determine
which patients, if any, derive clinical benefit from its use.
CONCLUSION
NAC may reduce the incidence of acutely increased
serum creatinine after administration of intravenous
contrast, but this finding was of borderline statistical
significance and was not observed in several prespeci-
fied subgroups. In addition, there is currently no direct
evidence that its use decreases healthcare costs, the risk
of permanent renal damage, or the need for acute dial-
ysis. Before NAC becomes the standard of care for all
patients receiving intravenous contrast, new randomized
trials evaluating its effect on clinically relevant outcomes
are required.
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